Issue Date: May 12, 2014
Pfizer Chases Merger Deal
Pfizer is still pushing to create a tax-advantaged U.K.-based drug giant even after AstraZeneca rejected its latest $106 billion takeover offer. To bolster Pfizer’s position, CEO Ian C. Read has promised British Prime Minister David Cameron that the company will keep significant operations in the U.K. The company also is highlighting the benefits of a merger in a new infographic on its merger-related website.
AstraZeneca . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society